Comprehensive evaluation of otorhinolaryngological symptoms in COVID-19 patients

Mohammad Salah Mahmoud, Mohamed Shehata Taha, Ossama Ibrahim Mansour, Michael Fadel, Ossama Mustafa Mady and Ahmed Abdelmoneim Teaima*

Abstract
Introduction: The aim of this study is to comprehensively evaluate the incidence and natural course of otorhinolaryngological symptoms of COVID-19 infection and its relations to each other and patient’s demographics.
Methods: This is a prospective study conducted on symptomatic adult patients proven to be infected with COVID-19. Detailed history was taken from each patient including onset of symptoms. Symptoms were followed up tightly. We focus on otorhinolaryngological (ORL) symptoms and their duration and onset in relation to other symptoms. Data were collected and analyzed in detail.
Results: Six-hundred eighty-six patients were included in the study, their age ranged from 19-75 years old, and of them 55.1% were males. Cough was found in 53.1% of cases followed by sore throat in 45.8%, anosmia/hyposmia in 42.3%, headache in 42%, rhinorrhea in 19.5%, dry mouth in 7.6%, globus in 6.1%, epistaxis in 4.4%, and hearing loss in 0.6%. In non-ORL symptoms, fever was found in 54.2%, malaise in 55.1%, dyspnea in 49.3%, and diarrhea in 27.2%. The first symptom was anosmia in 15.7% of cases, sore throat in 7.9%, and headache in 13.4% of cases. Fever was the first symptom in 22.7%, malaise in 25.1%, and diarrhea in 6.4%. Headache occurred for 5.5 ± 2 days, anosmia/hyposmia 3 to > 30 days, sore throat 4.1 ± 1.2 days, rhinorrhea 4.3 ± 1.1, cough 7.4 ± 2.5 days, fever 4.7 ± 2 days, and malaise 6.5 ± 2.4 days. The cluster of COVID-19-related symptoms showed nine principal components.
Conclusion: Otorhinolaryngological symptoms are main symptoms in COVID-19 infection, and they should be frequently evaluated to detect suspected cases especially in pauci-symptomatic patients and to properly manage infected patients.
Keywords: COVID-19, SARS-CoV-2, Anosmia, Cough, Sore throat

Background
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in Wuhan, China, at the end of 2019 [1]. In February 2020, it was officially called “COVID-19” by the WHO [2]. It became pandemic and has disastrous impact on health care and economic systems around the world. As of 20th April 2021, the WHO reports that 140 million people have been diagnosed with COVID-19 worldwide, with 3 million deaths, including 220 countries and territories. And mostly, the disease will continue to spread due to the reduction in strict measures [2, 3].
Seven coronaviruses are known to transmit to humans including SARS-CoV-2, SARS-CoV, and MERS-CoV (Middle East respiratory syndrome coronavirus) [4]. Growing evidence confirmed the nasal cavity is a vital area susceptible to SARS-CoV-2 infection. Researchers compared the pathology and virology of SARS-CoV-2, SARS-CoV, and MERS-CoV. They confirmed that these
pathogenic coronaviruses have different mainly pathogenic sites: SARS-CoV-2 (nose and throat), SARS-CoV (lung), and MERS-CoV (type-2 pneumocytes). Viral loads in the patient’s nasal cavity were higher than the viral loads in the pharynx, both symptomatic individuals and asymptomatic ones, hinting the nasal cavity as the first gateway for the initial infection [5, 6].

COVID-19 symptoms are very similar to seasonal flu with the most common symptoms of fever, cough, shortness of breath, malaise, muscle aches, sore throat, headache, and tiredness, loss of taste, and or smell [7]. COVID-19 could be manifested by several symptoms, ranging from asymptomatic/mild symptoms to severe illness and death [8]. ENT manifestations are not uncommon symptoms of COVID-19, especially in mild or moderate form of the disease [9].

Mapping the symptoms and percentages of the disease will assist to discover COVID-19 disease more and create more effective treatment protocols. The general symptoms were discussed in detail in the literature, but to the best of our knowledge, there is a gap in detailed research on ENT manifestations in COVID-19 in the literature. So, here we collect the data from 686 patients confirmed to be COVID-19-positive by PCR, and this is the largest and most detailed case series study in the literature about this topic.

**Table 1** Characteristics of the study population

| Variable | Count | %    |
|----------|-------|------|
| **Age category** |       |      |
| ≤ 50 years | 494  | 72.0%|
| > 50 years  | 192  | 28.0%|
| **Sex** |       |      |
| F         | 308  | 44.9%|
| M         | 378  | 55.1%|
| **Smoking** |      |      |
| Nonsmoker  | 472  | 68.8%|
| Ex-smoker  | 68   | 9.9% |
| Current smoker | 146  | 21.3%|
| **Risk factors for COVID-19** |       |      |
| HCW        | 228  | 33.2%|
| First responder | 136  | 19.8%|
| Close contact | 246  | 35.9%|
| Travel     | 4    | 0.6% |
| Other risk factors | 12   | 1.7% |
| **Number of risk factors for COVID-19** |       |      |
| Nil        | 196  | 28.6%|
| I          | 370  | 53.9%|
| II         | 104  | 15.2%|
| III        | 16   | 2.3% |
| **Comorbidities** |       |      |
| Hypertension | 148  | 21.6%|
| Asthma     | 64   | 9.3% |
| DM         | 124  | 18.1%|
| COPD       | 24   | 3.5% |
| CVS        | 20   | 2.9% |
| Sinonasal chronic disease | 64   | 9.4% |
| Other comorbidities | 50   | 7.3% |
| **Number of comorbidities** |       |      |
| Nil        | 354  | 51.9%|
| I          | 196  | 28.7%|
| II         | 116  | 17.0%|
| III        | 6    | 0.9% |
| IV         | 4    | 0.6% |
| V          | 6    | 0.9% |
| **Onset of symptoms** |       |      |
| Pre-diagnosis | 448  | 65.3%|
| Post-diagnosis | 238  | 34.7%|
| **Source of infection** |       |      |
| Unidentified | 334  | 48.7%|
| Identified  | 352  | 51.3%|
| **COVID-19 severity** |       |      |
| Mild       | 563  | 82.1%|
| Moderate   | 123  | 17.9%|

* Mean ± SD (minimum to maximum) = 42.3 ± 13.1 (19 to 75) years
Methods
This prospective study was conducted at the Ain Shams University Specialized Hospital at El-Obour City (assigned as a quarantine hospital during the pandemic for COVID-19 patients) from 1st May 2020 to 15th July 2020. This study included symptomatic adult patients proven to be infected with COVID-19 by PCR in nasopharyngeal swab. Exclusion criteria were asymptomatic patients, patients with mental or physical defects hindering communications, and patients with previous significant upper airway surgeries. Severely infected patients, who were admitted to intensive care unit, were excluded from the study. Lost patients in follow-up were excluded from the study.

Detailed history was taken from each patient personally by physicians or nurses completing sheets including demographic data, risk factors for COVID-19, comorbidities, and onset of symptoms. Symptoms were followed up tightly until complete recovery, or either patient was hospitalized or discharged for home isolation (followed by phone call). We focus on otorhinolaryngological (ORL) symptoms and their duration and onset in relation to other symptoms. ORL symptoms included in our study were cough, sore throat, anosmia, headache, nasal discharge, nasal obstruction, dysphagia, postnasal discharge, expectoration, dry mouth, earache, globus, vertigo, epistaxis, sneezing, tinnitus, facial pressure, otorrhea, stridor, deafness, neck swelling, and facial weakness. Non-ORL symptoms were fever, malaise, myalgia, diarrhea, and dyspnea.

Statistical methods
Data were analyzed using IBM® SPSS® Statistics version 26 (IBM® Corp., Armonk, NY). Continuous numerical variables are presented as mean and standard deviation and categorical variables as counts and percentages.

Associations are examined using the Phi (φ) coefficient (for nominal-nominal association), rank biserial (rbr) correlation coefficient (for ordinal-nominal association), or point biserial (rpb) correlation coefficient (for continuous-nominal association).

We conducted maximum likelihood principal component analysis (PCA) on the 27 symptoms that we screened for. The Kaiser-Meyer-Olkin (KMO) measure of sampling adequacy and Bartlett’s test of sphericity were used to examine suitability of data for component analysis. A KMO value of ≥ 0.6 and a P-value < 0.05 for the Bartlett’s test were identified as criteria for sampling adequacy and feasibility of PCA.

Initial component extraction was based on a cutoff criterion of eigenvalue greater than 1. Besides, a scree plot was examined, and all components with eigenvalues situated on the sharp descent of the plot before it levelled out were retained. Based on the results of initial factor extraction, 9 principal components were rotated using an orthogonal (Varimax) rotation solution.

Two-sided P-values < 0.05 are considered statistically significant.

Results
There were 686 patients included in our study aged 19 to 75 years old with 72% of them at or above 50 years old. A total of 65% were symptomatic before confirmation of diagnosis by PCR. A total of 82% were infected mildly (no need for hospitalization) (Table 1). Cough, sore throat, anosmia, and headache were the most prevalent ORL symptoms (Table 2) (Fig. 2), while non-ORL symptoms were presented as follows: malaise 55.1%, fever 54.2%, dyspnea 49.3%, myalgia 32.7%, and diarrhea 27.2% (Fig. 1).

Headache presented as first symptom in 13.4% and anosmia in 15.7%. Sore throat presented as second symptom in 18.4%, cough in 11.1%, anosmia in 10.8%, and nasal discharge in 9% (Table 3) (Figs. 2, 3, 4, 5).

In non-ORL symptoms, fever presented as first symptom in 22.7% and second in 13.1%. Malaise presented as first symptom in 25.1% and second in 10.2. Dyspnea

| Symptom           | Count | %   |
|-------------------|-------|-----|
| Cough             | 364   | 53.1%|
| Sore throat       | 314   | 45.8%|
| Anosmia           | 290   | 42.3%|
| Headache          | 288   | 42.0%|
| Nasal discharge   | 134   | 19.5%|
| Nasal obstruction | 116   | 16.9%|
| Dysphagia         | 92    | 13.4%|
| Postnasal discharge| 86   | 12.5%|
| Expectoration     | 82    | 12.0%|
| Dry mouth         | 52    | 7.6% |
| Earache           | 46    | 6.7% |
| Globus            | 42    | 6.1% |
| Vertigo           | 38    | 5.5% |
| Epistaxis         | 30    | 4.4% |
| Sneezing          | 28    | 4.1% |
| Tinnitus          | 26    | 3.8% |
| Facial pressure   | 20    | 2.9% |
| Otorrhea          | 6     | 0.9% |
| Stridor           | 4     | 0.6% |
| Deafness          | 4     | 0.6% |
| Neck swelling     | 0     | 0.0% |
| Facial weakness   | 0     | 0.0% |
presented as third symptom in 12.5% and fourth in 11.4%. Diarrhea presented as first symptom in 6.4% (Figs. 2, 3, 4, 5).

In relation to the duration of the symptom, anosmia took 13.4 ± 7.6 days, cough 7.4 ± 2.5 days, fever 4.7 ± 2 days, malaise 6.5 ± 2.4 days, and sore throat 4.1 ± 1.2 days (Supplemental Table 1).

By applying the principal component analysis for the cluster of COVID-19-related symptoms, it showed that groups of symptoms tend to be together. Group 1 symptoms are fever, headache, malaise, sore throat, cough, and dyspnea. Group 2 symptoms are nasal obstruction, nasal discharge, anosmia, etc. (Supplemental Table 2).

In terms of the association between the clinical symptoms and patient factors, as regards age, there was a statistically significant association between younger age and fever and cough. As regards gender, there was a statistically significant association between male gender and epistaxis. As regards smoking, there was a statistically significant association between smoking and headache, malaise, and sore throat. As regards asthma, there was a statistically significant association between asthma and malaise and post-nasal discharge. As regards diabetes mellitus, there was a statistically significant association between DM and fever, malaise, sneezing, and anosmia. As regards COPD, there was a statistically significant association between COPD and nasal obstruction, nasal discharge, epistaxis, dysphagia, and expectoration (Supplemental Table 3).

Discussion

COVID-19 disease rapidly spreads across every corner of the world. Otorhinolaryngologists may be in the front line due to the close contact with the mucus membrane of the upper respiratory tract, so discussing ORL symptoms in COVID infection in details may help in knowing the pauci-symptomatic patients. Our study primarily
is concerned with ORL symptoms of COVID-19 infection. It is done through our pandemic hospital on symptomatic patients confirmed to be infected by PCR. Six-hundred eighty-six patients were included in our study aged 42.3 ± 13.1 (19 to 75) years old, with 55.1% were male. In our study, close contact with an infected person formed the main risk factor in 35.9% of cases. About 28.6% of cases had no identified risk factor for infection. About 51.9% of cases included had no comorbidities. Most of the cases (65.3%) were symptomatic before diagnosis by PCR, and 51.3% of cases had identified source of infection. Most of the cases (82.1%) were mild COVID-19, and the rest were moderate to severe.

To date, our study may be the most detailed in the literature concerning ORL symptoms in COVID-19 patients, including duration of each symptom, its onset, relation to other symptoms, and patients’ demographics. Out of 686 patients, cough was the most prevalent ORL symptom found in 364 patients (53.1%) followed by sore throat in 314 (45.8%), anosmia and hyposmia in 290 (42.3%), headache in 288 (42%), rhinorrhea in 134 (19.5%), nasal obstruction in 116 (16.9%), and dry mouth in 52 (7.6%). Earache was found in 46 (6.7%), globus in 42 (6.1%), epistaxis in 30 (4.4%), tinnitus in 26 (3.8%), and hearing loss in 4 (0.6%). In non-ORL symptoms, fever was found in 372 (54.2%), malaise in 378 (55.1%), dyspnea in 388 (49.3%), myalgia in 224 (32.7%), and diarrhea in 186 (27.2%).

In their study on 1099 COVID-19 patients, Guan et al. found cough in 67.8%, dyspnea in 18.7%, sore throat in 13.9, and nasal obstruction in 4.8% [10]. Lechien et al. (in their study on 417 patients) found fever in 48%, cough in 78%, anosmia/hyposmia in 85.6%, and headache in 46% [11]. Speth et al. found fever in 88.5%, anosmia/hyposmia 61.2%, cough in 61.1%, and headache in 12.1% [12]. Bhatta et al. (in their study on 600 patients) documented sore throat in 88%, fever in 78.8%, anosmia/hyposmia in 63.6%, rhinorrhea in 51.3%, nasal obstruction in 33.5%, sneezing in 30.3%, dyspnea in 18.6%, cough in 87%, headache in 82%, myalgia in 67%, and diarrhea in 14.3% [13].

In 138 patients, Wang et al. found that common symptoms were fever (99%), fatigue (70%), dry cough (59%), anorexia (40%), myalgia (35%), dyspnea (3%), and expectoration (27%) [14]. In 155 patients, Elibol found that cough is (43.8%), anosmia (35.4%), sore throat (27%), nasal obstruction (12.9%), postnasal discharge (6%), otalgia (2%), rhinorrhea (9%), tinnitus (1.2%), hearing loss (0.6%). A total of 58.7% of the 155 patients were female, and 42.2% were male. ORL symptoms were seen more in females compared to males [15]. Lee et al. found anosmia in 15.3% of their patient group [16].

| Table 3 | Chronological order of ORL symptoms in COVID-19 patients |
| Symptom | Order of symptom in disease manifestation | Count | % |
| Headache | I | 92 | 13.4% |
| | II | 74 | 10.8% |
| | III | 42 | 6.1% |
| | IV | 38 | 5.5% |
| Nasal obstruction | I | 18 | 2.6% |
| | II | 34 | 5.0% |
| | III | 12 | 1.7% |
| | IV | 42 | 6.1% |
| Nasal discharge | I | 24 | 3.5% |
| | II | 62 | 9.0% |
| | III | 18 | 2.6% |
| | IV | 10 | 1.5% |
| | V | 8 | 1.2% |
| Postnasal discharge | III | 40 | 5.8% |
| | IV | 16 | 2.3% |
| Sneeze | III | 10 | 1.5% |
| | IV | 8 | 1.2% |
| Anosmia | I | 108 | 15.7% |
| | II | 74 | 10.8% |
| | III | 36 | 5.2% |
| | IV | 28 | 4.1% |
| | V | 38 | 5.5% |
| Sore throat | I | 42 | 6.1% |
| | II | 126 | 18.4% |
| | III | 38 | 5.5% |
| | V | 26 | 3.8% |
| | VII | 56 | 8.2% |
| Dysphagia | I | 4 | 0.6% |
| | II | 38 | 5.5% |
| | III | 12 | 1.7% |
| | V | 16 | 2.3% |
| Cough | I | 54 | 7.9% |
| | II | 76 | 11.1% |
| | III | 98 | 14.3% |
| | IV | 80 | 11.7% |
| | V | 28 | 4.1% |
| | VI | 2 | 0.3% |
| Dry mouth | | | |
| | | | |
| Earache | | | |
| Tinnitus | | | |
| Vertigo | | | |
| Expectoration | | | |
Borah et al. (in their study on 2000 patients) stated percentage of symptoms as follows: sore throat 80%, headache 76%, hyposmia anosmia 44%, nasal obstruction 28%, fever 93%, cough 85%, dyspnea 33%, malaise 14%, and abdominal symptoms 4% [17]. Ozcelik et al. (in their study on 116 patients) found that dry cough is (53.4%), dyspnea (38.8%), headache (37%) and nausea/vomiting (31%), hyposmia anosmia (37.9%), sore throat (32.7%), dysphagia (20.6%), globus sensation (13.7%), nasal obstruction (27.5%), rhinorrhea (13.7%), sneezing...
(12.9%), tinnitus (11.2%), hearing impairment (5.2%), vertigo (6.1%) [18].

Based on our study, the most common ORL symptoms are cough, sore throat, and anosmia/hyposmia, while the least common was hearing loss in four patients, and there were no cases of neck swelling or facial paralysis. It is not clear whether these four patients were symptomatic of the disease or were seen as an incidental finding to the disease.

In terms of the chronological order of ORL symptoms, anosmia/hyposmia was the first symptom in 15.7% of cases, second in 10.8%, and third in 5.2%. Sore throat
was the first symptom in 61% of cases, second in 18.4%, and third in 5.5%. Cough was the first symptom in 7.9% of cases, second in 11.1%, third in 14.3%, and fourth in 11.7%. Headache was the first symptom in 13.4% of cases, second in 10.8%, and third in 6.1%. Rhinorrhea was the second symptom in 9% of cases. Postnasal discharge was the third symptom in 5.8% of cases. In non-ORL symptoms, fever presented as first symptom in 22.7% and second in 13.1%. Malaise presented as first symptom in 25.1% and second in 10.2%. Dyspnea presented as third symptom in 12.5% and fourth in 11.4%. Diarrhea presented as first symptom in 6.4%

In terms of duration of each ORL symptoms, headache occurred for 5.5 ± 2 (2–14) days, anosmia/hyposmia 13.4 ± 7.6 (3 to > 30) days, sore throat 4.1 ± 1.2 (2–10) days, rhinorrhea 4.3 ± 1.1 (2–7) days, cough 7.4 ± 2.5 days, and dry mouth 4.7 ± 1.6. In non-ORL symptoms, fever occurred for 4.7 ± 2 (1–14) days, malaise 6.5 ± 2.4 (3–17) days, diarrhea 5.1 ± 2.6 (2–14) days, and dyspnea 8.6 ± 5.5 (4 to > 30) days.

According to Borah et al., ORL symptoms of 78% of cases resolved in 10–20 days, but anosmia/hyposmia might need some more time [17], while Bhatta et al. found the time required for symptom resolution was for dyspnea (1.3 ± 0.2 days), fever (2.4 ± 0.9 days), anosmia/hyposmia (14.3 ± 2.8 days), nasal obstruction (10.1 ± 3.1 days), sneezing (8.3 ± 1.3 days), sore throat (7.6 ± 2.3 days), and rhinorrhea (6.3 ± 1.2 days) (13). Teaima et al. found smell and taste dysfunctions happened before other COVID-19 symptoms in 19.4% of cases, with other COVID-19 symptoms in 37.1% and after in 43.5%. These dysfunctions occurred suddenly in 80.4% and gradually in 19.6%. In 6-month follow-up, 66% of smell/taste symptoms recovered completely, 22.1% partially, while 11.9% did not recover [19]. Mahmoud et al. found that 50.6% of hospitalized COVID-19-infected patients complained of olfactory/gustatory dysfunctions, and 76.5% of them complained upper respiratory tract symptoms before olfactory/gustatory symptoms [20].

Principal component analysis for the cluster of COVID-19-related symptoms shows 9 principal components. Fever, headache, malaise, sore throat, cough, and dyspnea formed one component. Nasal obstruction, rhinorrhea, postnasal discharge, and anosmia/hyposmia formed one component. Dry mouth and myalgia formed one component. Dysphagia, diarrhea, and globus formed one component. Vertigo, tinnitus, and hearing loss formed one component. Ozcelik et al. found that cough and dyspnea were more common in elder patients (over 60 years), and that anosmia/hyposmia, headache, and sore throat were common in younger patients and in female. Anosmia/hyposmia and sneezing were more common in patients with allergic rhinitis, while headache was more common in hypertensive and diabetic patients. Dyspnea was more common in patient with chronic chest diseases [18].

In our study, we found a statistically significant association between younger age and fever cough and association between male gender and epistaxis. As regards smoking, there is a statistically significant association between smoking and headache, malaise, and sore throat and a statistically significant association between asthma and malaise and post-nasal discharge. As regards diabetes mellitus, there is a statistically significant association between DM and fever, malaise, sneezing, and anosmia. As regards COPD, there was a statistically significant association between COPD and nasal obstruction, nasal discharge, epistaxis, dysphagia, and expectoration.

Limitations of this study are that 72% of included patients were at or above 50 years old, and that we could not follow-up symptoms in severely infected patients in intensive care unit.

**Conclusion**

Otorhinolaryngological symptoms are main symptoms in COVID-19 infection, and they should be frequently evaluated to detect suspected cases especially in pauci-symptomatic patients and to properly manage infected patients.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s43163-022-00263-5.

**Additional file 1: Supplemental Table 1.** Chronological pattern (duration) of symptoms (ORL, non-ORL) in COVID-19 patients.

**Additional file 2: Supplemental Table 2.** Results of principal component analysis for the cluster of COVID-19-related symptoms showing symptom loadings on the 9 principal components extracted and rotated using an orthogonal (Varimax) rotation solution.

**Additional file 3: Supplemental Table 3.** Association between symptoms and demographic and epidemiological variables.

**Acknowledgements**

The authors have no acknowledgements to disclose.

**Authors’ contributions**

MSM, formed the concept and methods and collected the data; MST, supervised the work and reviewed the manuscript; OIM, critically reviewed the article and supervised the work; MF, collected the data and review the literature;
O MM, collected the data and reviewed the literature; AAT, formulated the design, collected the data, prepared and wrote the manuscript, and the corresponding author. The authors read and approved the final manuscript.

Funding
The authors have no funding to disclose.

Availability of data and materials
All data generated or analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author.

Declarations

Ethics approval and consent to participate
This study protocol was reviewed and approved by the Ain Shams University, Faculty of Medicine Institutional Review Board, approval number FMASU R87/2020. All patients signed informed written consent prior study started. This study complied with the guidelines for human studies and was conducted ethically in accordance with the World Medical Association Declaration of Helsinki.

Consent for publication
Not applicable

Competing interests
Dr. Mohamed Shehata Taha is a co-author of this study and editorial board member of the journal. He declares a competing interest for this submission. He has not handled this manuscript. The rest of the authors declare that they have no competing interests.

Received: 19 April 2022  Accepted: 20 May 2022
Published online: 08 June 2022

References
1. Wang Y, Wang Y, Chen Y, Qin Q (2020) Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 92(6):568–576
2. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ et al (2020) The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 7(1):11
3. World Health Organization. Coronavirus disease 2019 (COVID-19) situation report. https://www.who.int/docs/default-source/coronaviruse/situation-reports, Accessed date: 24 Apr 2021.
4. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L et al (2020) Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 87:18–22
5. Rocke B, Kuiken T, Herfst S, Bestebroer T, Lamers MM, Ouwe BM et al (2020) Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 368(6494):1012–1015
6. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z et al (2020) SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 382:1177–1179
7. Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, et al (2020) Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis 20:9.e238–e244
8. Lovato A, Filippis C, Marioni G (2020) Upper airway symptoms in coronavirus disease 2019 (COVID-19). Am J Otolaryngol. 41(3):102–107
9. Krajewska J, Krajewski W, Zub K, Zatorcki T (2020) COVID-19 in otorhinolaryngologist practice: a review of current knowledge. European Archives of Oto-Rhino-Laryngology 277(7):1885–1897
10. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX et al (2020) China Medical Treatment Expert Group for COVID-19: Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 382(18):1708–1720
11. Lechien JR, Chiesa-Estomba CM, Siani DR, Horoi M, Le Bon SD, Rodriguez A et al (2020) Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 277(8):2251–2261
12. Speth MM, Singer-Cornelius T, Oiberle M, Gengler I, Brockmeier SJ, Seda-ghat AR (2020) Olfactory dysfunction and sinonasal symptomatology in COVID-19: prevalence, severity, timing, and associated characteristics. Otolaryngol Head Neck Surg. 163(1):114–120
13. Bhatta S, Gandhi S, Saindani SJ, Ganesuni D, Ghanpur AD (2021) Otorhinolaryngological manifestations of coronavirus disease 2019: a prospective review of 600 patients. J Laryngol Otol. 135(3):206–211
14. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan. China. JAMA. 323(11):1061–1069
15. Elbol E (2021) Otorhinolaryngological symptoms in COVID-19. Eur Arch Otorhinolaryngol. 278(4):1233–1236
16. Lee Y, Min P, Lee S, Kim SW (2020) Prevalence and duration of acute loss of smell or taste in COVID-19 patients. J Korean Med Sci. 35(18):174
17. Borah H, Das S, Goswami A (2021) Otorhinolaryngological manifestations and its management in COVID-19 patients. Indian J Otolaryngol Head Neck Surg. 1–4
18. Ozcelik KM, Egrilmez OK, Ozcelik MA, Guven M (2021) Otorhinolaryngological manifestations of hospitalized patients with confirmed COVID-19 infection. Eur Arch Otorhinolaryngol. 278(5):1675–1685
19. Teaima AA, Salem OM, Teama M, Mansour OI, Taha MS, Badr FM et al (2021) Patterns and clinical outcomes of olfactory and gustatory disorders in six months: prospective study of 1031 COVID-19 patients. Am J Otolaryngol 43(1):103259
20. Mahmoud MS, Taha MS, Mansour OI, Amir M, Hamdy TA, Ezzat WF et al (2022) Prevalence and outcomes of olfactory and gustatory dysfunctions in hospitalized SARS-CoV-2-infected patients. Egypt J Otolaryngol 38:19

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com